Objective
to assess the clinical efficacy of dual-therapy sirolimus-eluting and CD34 + antibody coated Combo stent (DTS) compared to Sirolimus-eluting ORSIRO stent
Study
multicentre non-inferiority randomised trial (margin 2.1%)
Population
all comers
Endpoints
target lesion failure as cardiac death, MI or target lesion revascularisation at 12 months
Conclusion
the DTS did not confirm non-inferiority to SES at 12 months
Jakobsen et al. Circulation. 2021;143:2155-65